InsidersTradesSigma
Follow the 宏源药业 stock price and the full insider trade history of the company, a publicly traded company based in China. Shares trade on the CN market, under the authority of SSE / SZSE (CSRC). Operating in the Health Care sector, 宏源药业 has recorded 7 reports. Market capitalisation: €7.7bn. The latest transaction was reported on 8 August 2024 (Sale). Among the most active insiders: 雷高良. All data is accessible without an account.
7
Insider Decl.
n/a
Thresholds
n/a
n/a
Buy Volume
€910,638
7 ops.
Sell Volume
7Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 20,946 of 29,063 companies
36.9
score / 100
Value28
Quality46
FCF yld-4.4%
Earn yld1.6%
EV/EBITDA22.7x
ROE5.6%
Gross mgn19%
Net mgn6.1%
Debt/EBITDA1.5x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 8 August 2024
Declarations7 total
7 of 7 declarations
关于 宏源药业
宏源药业是一家专注于健康和制药领域的公司。它在XSHE市场上市。